Seroprevalence of SARS-CoV-2 in Asymptomatic Frontline COVID-19 HCWs

Completed

• Conditions: Covid19
• Interventions: Diagnostic Test: IgG SARS CoV 2 antibodies

• Registration Number: NCT04563247
• Lead Sponsor: Lahore General Hospital

Brief Summary

This study is about the current knowledge on the immunological changes observed in various healthcare workers in this part of the world, who remained asymptomatic while working in high exposure areas of COVID-19 infection.

Detailed Description

Coronaviruses (CoVs) are enveloped, single positive-strand RNA viruses belonging to the large subfamily Coronavirinae, which can infect mammals and several other animals.The continued spread of coronavirus disease 2019 (COVID-19) has prompted widespread concern around the world, and the World Health Organization (WHO), on 11 March 2020, declared COVID-19 a pandemic. Studies on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) showed that virus-specific antibodies were detectable in 80-100% of patients at 2 weeks after symptom onset. Currently, the antibody responses against SARS-CoV-2 remain poorly understood and the clinical utility of serological testing is unclear. Little is known about the kinetics, tissue distribution, cross-reactivity and neutralization antibody response in COVID-19 patients. Asymptomatic cases are common but to date there are scarce epidemiological surveys that provide a clear percentage of asymptomatic cases.

A large number of healthcare workers have been infected with the virus worldwide, presenting with severe symptoms to no symptoms at all, in which case being diagnosed on contact tracing only. The seropositivity rate in previously undiagnosed healthcare workers has been reported in different regions of the world. In a combined study of three hospitals of Turkey, the seropositivity rate of the previously undiagnosed HCWs was 2.7%. A study done in China revealed 17.5 % seropositivity rate.

This study will aim to comprehensively review the current knowledge on the immunological changes observed in various healthcare workers in this part of the world, who remained asymptomatic while working in high exposure areas of COVID-19 infection.

Study Timeline

• Study Start: 2020-07-01
• Study First Submitted: 2020-09-20
• Study First Submitted QC: 2020-09-20
• Study First Posted: 2020-09-24
• Primary Completion: 2021-02-08
• Study Completion: 2021-02-08
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-12
• Last Update Posted: 2022-02-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 970

Inclusion Criteria

• All HCWs who had been working in high exposure areas of COVID 19

Exclusion Criteria

• Any HCW of high exposure areas of COVID 19 who suffered from COVID 19 themselves diagnosed on PCR or clinically

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Asymptomatic frontline HCWs for COVID 19	IgG SARS CoV 2 antibodies	All healthcare workers who worked in high exposure areas of hospital dealing with COVID 19.

Primary Outcome Measures

Name	Time	Method
SARS CoV 2 IgG antibodies	3 months	The presence or absence of SARS CoV 2 antibodies in serum of HCWs

Trial Locations

Locations (1)

Lahore General Hospital; 🇵🇰 Lahore, Punjab, Pakistan